SAGE Therapeutics (SAGE) Misses Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress
August 12, 2015 6:30 AM EDTGlobal Phase 3 STATUS Trial to Evaluate SAGE-547 as a Treatment for SRSE Now Open for Enrollment
Novel, Proprietary Second-Generation Product Candidates Poised to Enter Phase 1 in 2015
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2015.
"We are pleased to have moved SAGE-547 into Phase 3 development with the initiation of the STATUS Trial, which will be conducted with the U.S. Food and Drug Administration (FDA) agreement under a Special Protocol... More
SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress
August 12, 2015 6:30 AM EDTGlobal Phase 3 STATUS Trial to Evaluate SAGE-547 as a Treatment for SRSE Now Open for Enrollment
Novel, Proprietary Second-Generation Product Candidates Poised to Enter Phase 1 in 2015
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2015.
"We are pleased to have moved SAGE-547 into Phase 3 development with the initiation of the STATUS Trial, which will be conducted with the U.S. Food and Drug Administration (FDA) agreement under a Special Protocol... More
